Opthea Ltd
OPT•Health Care•Biotechnology•Last updated: Dec 25
About
Opthea Ltd is a biotechnology company focused on the development of therapies for eye diseases. The company is primarily engaged in advancing its lead product candidate, OPT-302, a novel VEGF-C/D 'trap' therapy for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Opthea's operations are centered around clinical trials and research and development activities aimed at addressing unmet medical needs in ophthalmology.
Share Price Chart
Company Details
- Sector
- Health Care
- Industry
- Biotechnology
- ASX Code
- OPT
Related Shares
Investor Resources
Should you buy Opthea Ltd right now?
While OPT looks interesting right now, our experts have just put together a full report on the ultimate ASX investment portfolio - designed for growth and passive income.
Join the Rask weekly investment newsletter to get the names, right now